[go: up one dir, main page]

AR057152A1 - Sistema terapeutico transdermico - Google Patents

Sistema terapeutico transdermico

Info

Publication number
AR057152A1
AR057152A1 ARP060104447A ARP060104447A AR057152A1 AR 057152 A1 AR057152 A1 AR 057152A1 AR P060104447 A ARP060104447 A AR P060104447A AR P060104447 A ARP060104447 A AR P060104447A AR 057152 A1 AR057152 A1 AR 057152A1
Authority
AR
Argentina
Prior art keywords
active ingredient
adhesive solution
transdermal therapeutic
adhesive layer
silicone
Prior art date
Application number
ARP060104447A
Other languages
English (en)
Original Assignee
Novartis Ag
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Lohmann Therapie Syst Lts filed Critical Novartis Ag
Publication of AR057152A1 publication Critical patent/AR057152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sistemas Terapéuticos Transdérmicos que poseen una capa adhesiva de silicona, a Sistemas Terapéuticos Transdérmicos que proveen concentraciones en plasma específicas, a su elaboracion y uso. Reivindicacion 1: Un Sistema Terapéutico Transdérmico (STT) que comprende a) una capa posterior, b) una capa reservorio que comprende uno o más ingredientes farmacéuticamente activos y uno o más polímeros, c) una capa adhesiva que comprende un taquificante y un polímero de silicona. Reivindicacion 8: El STT de acuerdo con cualquiera de las reivindicaciones 1 a 6, caracterizado en que el ingrediente activo está seleccionado del grupo integrado por agonistas de alfa-adrenoreceptor, agonistas de beta-adrenoreceptor, bloqueantes de alfa- adrenoreceptor, analgésicos anestésicos, analgésicos no anestésicos, androgenos, anestésicos, antialérgicos, antiandrogenos, antianginales, antiarrítmicos, penicilinas, antidiabéticos, antihistamínicos, agentes antimigrana, alcaloides ergot hidratados, antagonistas de Ca++, antagonistas de serotonina, inhibidores de agregacion plaquetaria, antidepresivos, bronquiolíticos, estrogenos, gestágenos, vasodilatadores, hormonas, fármacos anti-demencia. Reivindicacion 9: El STT de acuerdo con cualquiera de las reivindicaciones 1 a 6, caracterizado en que el ingrediente activo está seleccionado el grupo integrado por tacrina, rivastigmina, donepezil, galantamina, fisostigmina, huperzina A y las sales farmacologicamente aceptables de las mismas. Reivindicacion 20: Un proceso para elaborar un STT de acuerdo con cualquiera de las reivindicaciones precedentes que comprende las etapas de a) la elaboracion del ingrediente activo en solucion adhesiva; b) el recubrimiento del ingrediente activo en solucion adhesiva; c) el secado del ingrediente activo en solucion adhesiva, d) la elaboracion de la solucion adhesiva de silicona; e) el recubrimiento de la solucion adhesiva de silicona, f) el laminado de la capa adhesiva de silicona al fármaco en la capa adhesiva, g) la perforacion y el embolsado.
ARP060104447A 2005-12-01 2006-10-10 Sistema terapeutico transdermico AR057152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74151105P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
AR057152A1 true AR057152A1 (es) 2007-11-21

Family

ID=37716856

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060104447A AR057152A1 (es) 2005-12-01 2006-10-10 Sistema terapeutico transdermico
ARP140102752A AR097045A2 (es) 2005-12-01 2014-07-24 Sistema terapéutico transdérmico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140102752A AR097045A2 (es) 2005-12-01 2014-07-24 Sistema terapéutico transdérmico

Country Status (31)

Country Link
US (3) US20070128263A1 (es)
EP (5) EP3235495A1 (es)
JP (3) JP2009517468A (es)
KR (7) KR20220156666A (es)
CN (2) CN102048713A (es)
AR (2) AR057152A1 (es)
AT (1) AT11185U1 (es)
AU (1) AU2006320919B2 (es)
BR (2) BRPI0619758A2 (es)
CA (1) CA2563110A1 (es)
DE (2) DE14163637T1 (es)
DK (5) DK2292219T3 (es)
EC (1) ECSP088469A (es)
ES (1) ES2414455T3 (es)
GT (1) GT200800075A (es)
HK (1) HK1153646A1 (es)
IL (4) IL191311A (es)
MA (1) MA30022B1 (es)
MY (2) MY151020A (es)
NO (1) NO20082753L (es)
NZ (1) NZ568273A (es)
PH (2) PH12013500772B1 (es)
PL (1) PL2292219T4 (es)
PT (1) PT2292219E (es)
RU (1) RU2450805C2 (es)
SG (1) SG2014014989A (es)
SI (1) SI2292219T1 (es)
TN (1) TNSN08238A1 (es)
TW (1) TWI389709B (es)
WO (1) WO2007064407A1 (es)
ZA (1) ZA200803882B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
JP5706882B2 (ja) * 2009-04-17 2015-04-22 スリーエム イノベイティブ プロパティズ カンパニー シリコーンゲル接着剤構成体
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
ES2712989T3 (es) 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
WO2011073362A1 (en) 2009-12-18 2011-06-23 Novartis Ag Process for the preparation of optically active compounds using pressure hydrogenation
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US8962014B2 (en) 2009-12-22 2015-02-24 Acino Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
RU2578971C2 (ru) * 2010-06-17 2016-03-27 Лтс Ломанн Терапи-Системе Аг Трансдермальное введение мемантина
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
WO2012012417A1 (en) 2010-07-21 2012-01-26 3M Innovative Properties Company Transdermal adhesive compositions, devices, and methods
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120046383A1 (en) * 2010-08-19 2012-02-23 Terumo Kabushiki Kaisha Silicone rubber composition
PT3590949T (pt) 2010-10-01 2022-08-02 Modernatx Inc Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
ES2545094T3 (es) 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR101054317B1 (ko) * 2011-01-28 2011-08-08 신신제약 주식회사 리바스티그민을 함유하는 경피흡수제제
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
BR112013029945A2 (pt) * 2011-05-20 2017-01-31 Sk Chemicals Co Ltd emplastro contendo rivastigmina
EP2752188B1 (en) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Adhesive patch
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
KR101399035B1 (ko) * 2011-12-22 2014-05-28 주식회사 트랜스덤 리바스티그민을 함유하는 경피흡수제제
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
AU2012371935A1 (en) 2012-02-28 2014-09-11 Nichiban Co., Ltd. Transdermal patch
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
EP2847329A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF CYTOPLASMA AND CYTOSCELETTE PROTEINS
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013150542A2 (en) * 2012-04-05 2013-10-10 Sparsha Pharma International Private Limited A transdermal patch for treatment of dementia or alzheimer type dementia
PL2859892T3 (pl) * 2012-06-12 2023-10-16 KM Transderm Ltd. Plaster
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
JP2015530375A (ja) * 2012-08-15 2015-10-15 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 多層薬物送達システム
US20150209302A1 (en) 2012-09-03 2015-07-30 Nipro Patch Co., Ltd. Adhesive skin patch
KR20140038237A (ko) * 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
WO2014051128A1 (ja) * 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
RU2560668C2 (ru) * 2013-03-04 2015-08-20 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальный седативный фармацевтический гель для лечения психоэмоциальных расстройств
AR095259A1 (es) * 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
JP6391664B2 (ja) * 2013-03-15 2018-09-19 エヌエーエル ファーマスーティカル グループ リミテッド リバスチグミンを含む、経皮薬物送達システム
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
TWI626953B (zh) * 2013-06-12 2018-06-21 Km Transderm Ltd Percutaneous absorption preparation
ES2897696T3 (es) 2013-06-12 2022-03-02 Km Transderm Ltd Hoja adhesiva para aplicación sobre la piel y preparación de absorción percutánea que utiliza la misma
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
WO2015087926A1 (ja) 2013-12-12 2015-06-18 久光製薬株式会社 積層型貼付剤
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
WO2015156990A1 (en) 2014-04-08 2015-10-15 Teikoku Pharma Usa, Inc. Rivastigmine transdermal compositions and methods of using the same
WO2015174502A1 (ja) 2014-05-15 2015-11-19 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
EP3145504B1 (en) 2014-05-20 2023-07-26 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
CN204119542U (zh) 2014-09-24 2015-01-21 上海荣威塑胶工业有限公司 一种ptc加热器
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
US10314791B2 (en) 2014-12-05 2019-06-11 KM Transderm Ltd. Adhesive sheet for attachment to skin and percutaneous absorption preparation using same
DE102015107743A1 (de) 2015-05-18 2016-11-24 Bsn Medical Gmbh Silikongelbeschichtete adhäsive Schichtstruktur
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
EP3501518A4 (en) 2016-08-22 2020-04-29 Kyukyu Pharmaceutical Co., Ltd. TRANSDERMAL PATCH
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) * 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
KR102033686B1 (ko) 2017-05-19 2019-10-18 보령제약 주식회사 도네페질을 함유하는 마이크로니들 경피 패치
WO2019048425A1 (en) 2017-09-05 2019-03-14 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL DELIVERY OF RIVASTIGMINE
JP2021515789A (ja) * 2018-03-13 2021-06-24 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
CA3092757A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
EP3764997A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
CN112533594A (zh) 2018-06-19 2021-03-19 罗曼治疗系统股份公司 含有卡巴拉汀的透皮治疗系统
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
TWI781370B (zh) 2019-01-31 2022-10-21 日商久光製藥股份有限公司 貼附劑
WO2021005118A1 (en) * 2019-07-09 2021-01-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel adhesive
EP3996692A1 (en) * 2019-07-09 2022-05-18 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂
WO2024160939A1 (en) * 2023-02-01 2024-08-08 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of huperzine a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6316023B1 (en) 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
DE10103860B4 (de) 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
DE10159745A1 (de) * 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
PT1509232E (pt) * 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
UA83645C2 (ru) * 2002-10-24 2008-08-11 Мерц Фарма Гмбх Унд Ко. Кгаа Фармацевтический продукт, который содержит производное 1-аминоциклогексана и ингибитор ацетилхолинестеразы, его применение
US20070166363A1 (en) 2004-02-19 2007-07-19 Lane Roger M Use of cholinesterase inhibitors for treating vascular depression
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2596889B1 (en) * 2011-11-23 2017-04-26 Sandvik Intellectual Property AB A cutting insert and a milling tool

Also Published As

Publication number Publication date
GT200800075A (es) 2010-06-01
CN101312717A (zh) 2008-11-26
ECSP088469A (es) 2008-07-30
KR20170033449A (ko) 2017-03-24
TW200732001A (en) 2007-09-01
PH12013500772B1 (en) 2018-04-20
US20130266633A1 (en) 2013-10-10
EP2292219B1 (en) 2013-06-12
JP2013177419A (ja) 2013-09-09
EP1959937A1 (en) 2008-08-27
DK201300059U1 (da) 2013-04-29
US20140134230A1 (en) 2014-05-15
DK201600113U1 (da) 2017-01-13
JP5938612B2 (ja) 2016-06-22
MY162986A (en) 2017-07-31
BRPI0619758A2 (pt) 2011-10-18
DK201300015Y4 (da) 2016-02-12
IL234291A (en) 2017-02-28
ES2414455T3 (es) 2013-07-19
KR20220156666A (ko) 2022-11-25
EP3235495A1 (en) 2017-10-25
SG2014014989A (en) 2014-06-27
HK1153646A1 (en) 2012-04-05
JP6298034B2 (ja) 2018-03-20
DK2292219T3 (da) 2013-06-24
KR20080071581A (ko) 2008-08-04
KR20210008440A (ko) 2021-01-21
KR20180050441A (ko) 2018-05-14
IL191311A (en) 2015-02-26
PT2292219E (pt) 2013-06-24
DE202006021172U1 (de) 2013-05-07
EP2292219A1 (en) 2011-03-09
CA2563110A1 (en) 2007-06-01
EP2786748A1 (en) 2014-10-08
TNSN08238A1 (en) 2009-10-30
NZ568273A (en) 2011-06-30
JP2016104737A (ja) 2016-06-09
AU2006320919A1 (en) 2007-06-07
MA30022B1 (fr) 2008-12-01
KR20130143729A (ko) 2013-12-31
EP2292219B9 (en) 2015-02-18
ZA200803882B (en) 2009-03-25
AU2006320919B2 (en) 2011-04-28
RU2450805C2 (ru) 2012-05-20
DE14163637T1 (de) 2015-06-03
CN102048713A (zh) 2011-05-11
TWI389709B (zh) 2013-03-21
JP2009517468A (ja) 2009-04-30
DK201300015U1 (en) 2013-02-08
MY151020A (en) 2014-03-31
NO20082753L (no) 2008-08-19
PL2292219T4 (pl) 2014-03-31
AT11185U1 (de) 2010-06-15
WO2007064407A1 (en) 2007-06-07
PH12013500771A1 (en) 2016-01-18
EP2286802A1 (en) 2011-02-23
IL234364A (en) 2016-06-30
DK201300059U3 (da) 2013-05-13
DK201300014U3 (da) 2013-05-13
US20070128263A1 (en) 2007-06-07
BR122013013162A2 (pt) 2015-06-30
DK201300014U1 (da) 2013-02-08
AR097045A2 (es) 2016-02-17
RU2008126459A (ru) 2010-01-20
KR20140072108A (ko) 2014-06-12
DK201600113Y4 (da) 2017-06-09
IL250734A0 (en) 2017-04-30
PH12013500772A1 (en) 2016-01-18
SI2292219T1 (sl) 2013-08-30
PL2292219T3 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
AR057152A1 (es) Sistema terapeutico transdermico
KR102536696B1 (ko) 향상된 투과성을 가지는 약물학적 조성물
JP5049268B2 (ja) マイクロニードルデバイスおよびマイクロニードル付き経皮薬物投与装置
AR072492A1 (es) Dispositivo y administracion transdermica de estrogeno
MX2022006681A (es) Sistema de suministro transdermico de donepezilo.
AR039336A1 (es) Sistemas analgesicos transdermicos con potencial de abuso reducido
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
ES2106818T3 (es) Composicion multicapa que contiene antagonistas de histamina o secotina.
AR037081A1 (es) Composicion para el suministro transdermico de fentanilo
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR048862A1 (es) Aparatos y metodos para el suministro transdermico de una vacuna antigripal
CN105982842B (zh) 微针制剂以及微针制剂的制造方法
JP6369992B2 (ja) 溶解型マイクロニードル製剤
NO20031875L (no) Transdermale legemiddelleveringsanordninger med belagte mikrofremspring
NZ605352A (en) Process for producing glycosaminoglycans
WO2012115207A1 (ja) マイクロニードルデバイス用生理活性非水組成物及びマイクロニードル上に付着している生理活性非水組成物
PA8815901A1 (es) Sistema de administracion de drogas con efecto estabilizante
CN109310646A (zh) 增强递送的肾上腺素组合物
TWI659754B (zh) Micro needle sheet
JP2023159150A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
JP2024012484A (ja) 増強された透過を有する医薬組成物
NZ608598A (en) A transdermal drug administration device
BRPI0514252A (pt) sistema de elastoplasto de microprotusões sem agulha
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
US20170000751A1 (en) Composition for accelerating penetration through skin, preparation for transdermal administration, and skin patch preparation

Legal Events

Date Code Title Description
FC Refusal